Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oxford Nanopore
Oxford, United Kingdom
- Ownership
- Private
- Employees
- ~1315
- Development stage
- Other
01
Overview
Oxford Nanopore's sequencing technology is broadly adopted worldwide, featured in over 8,600 scientific publications, and has enabled critical advances in genomics, clinical research, and pandemic response, including COVID-19 surveillance in more than 70 countries[6][8].
- Therapeutic areas
- Infectious DiseasesRare DiseasesGastroenterologyOtherOncology
- Modalities
- DeviceNanopore-based sequencing technology
- Industry
- Molecular Diagnostics
02
Partnerships
University of OxfordHan Remaut laboratory (VIB/Vrije Universiteit Brussel)
Beyond the preview
Go deeper on Oxford Nanopore.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxford Nanopore.